Peptide Plug

Age Verification

Peptide Plug is a research and organization tool intended for adults 18 years of age or older. By continuing, you confirm you are at least 18.

Reference only · Not medical advice · For adults 18+ · No dosing information is published here
Peptide Plug
HomeResearchEducationToolsGuidesCompareAboutOpen the App
Home/Research library/Retatrutide
Metabolic

Retatrutide — reference

Investigational triple GLP-1/GIP/glucagon receptor agonist studied for weight management.

Regulatory statusInvestigational
Published half-life~5.5–6 days (130–140h)
Evidence levelClinical trial
CategoryMetabolic

Regulatory status

Investigational. Investigational and not FDA-approved. Verify current status directly with the FDA.

Reported cautions

⚠ Worth knowing. Do not treat clinical-trial information as personal instructions.

Pharmacokinetics

Published figures give an elimination half-life of ~5.5–6 days (130–140h). Phase 2/3 data; not FDA-approved. Some sources cite up to 150–180h.

This figure is tagged Clinical trial in our evidence system. This figure comes from published human trial data rather than an approved label. It is real data, but it has not been through regulatory review, and the compound may not be approved for any use. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.

Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →

What Peptide Plug does and does not publish

This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.

Frequently asked

Is Retatrutide FDA-approved?
Investigational. Investigational and not FDA-approved. Verify current status directly with the FDA.
What is the half-life of Retatrutide?
Published figures give ~5.5–6 days (130–140h). Phase 2/3 data; not FDA-approved. Some sources cite up to 150–180h.
How reliable is that half-life figure?
It is tagged “Clinical trial” in our system. This figure comes from published human trial data rather than an approved label. It is real data, but it has not been through regulatory review, and the compound may not be approved for any use.
What cautions are associated with Retatrutide?
Do not treat clinical-trial information as personal instructions.
Does Peptide Plug publish dosing for Retatrutide?
No. This library publishes regulatory status, general context and pharmacokinetics only. Dose, frequency and cycle information is deliberately absent from these public pages — those are clinical decisions, not reference data.
Does Peptide Plug sell Retatrutide?
No. We do not sell, supply, source or link to vendors for any compound, and we have no affiliate arrangements with suppliers. Peptide Plug is a tracking and calculation tool.

Related tools

Free, no account required.

GLP-1 Dose Calculator
Reconstitution and draw-volume math.
GLP-1 Titration Planner
Escalation schedule with real dates.
Half-Life Visualizer
Estimated rise-and-fall curve between doses.
Reconstitution Calculator
Vial math including blend support.
Medication Storage Calculator
Discard windows from published guidance.
Half-Life Data Table
All 86 compounds with evidence tags.
Reference information, not medical advice. This page describes regulatory status and published pharmacokinetics. It does not tell you whether to use this compound, how much to use, how often, or whether it is safe for you. Peptide Plug does not sell, supply or source any compound. Those decisions belong to you and a licensed clinician.

Part of the Peptide Plug research library · How we source our figures